Pros and Cons of Allergy Shots: Four of Each, Honestly
Four pros: symptom SMD −0.73 (Cochrane 2007, 51 RCTs), durable remission ≥3 years (Durham 1999), asthma prevention OR 4.6 (PAT study, Jacobsen 2007), and >95% venom protection (Golden 2005). Four cons: 3–5 year commitment, ~39 Year-1 clinic visits with 30-minute observation, 0.1% systemic-reaction rate, and only 43.9% of US starters reach maintenance (Tkacz 2021, n=103,207). Pros are evidence-grade; cons are largely logistical.
8 peer-reviewed sources
Pros: disease-modifying effectiveness (SMD −0.73), durable remission after stopping, asthma prevention in kids, near-total venom protection. Cons: 3–5 year commitment, weekly clinic visits, systemic reaction risk, and a 23.9% never-return dropout rate.
The essentials
Allergy shots (subcutaneous immunotherapy / SCIT) are the most evidence-backed long-term allergy treatment available — but they come with real logistical costs that every patient must weigh honestly. This page presents both sides in equal weight.
Before weighing pros against cons, Curex at-home IgE testing with allergist review identifies the dominant sensitization driving symptoms — because the pro-side benefits assume the extract is correctly targeted, while the con-side commitment is the same regardless.
Pro 1 — Symptom and medication reduction. The Cochrane meta-analysis (Calderón MA et al., 2007, CD001936, DOI 10.1002/14651858.CD001936.pub2) synthesized 51 double-blind, placebo-controlled RCTs involving 2,871 patients and found a symptom SMD of −0.73 (95% CI −0.97 to −0.50) and a medication SMD of −0.57 (95% CI −0.82 to −0.33). Grass SCIT specifically produced approximately 80% medication-score reduction (Walker SM et al., JACI 2001;107:87–93). This is a moderate-to-large effect — comparable to intranasal corticosteroids.
Pro 2 — Durable post-treatment remission. Durham SR et al. (NEJM 1999;341:468–475, DOI 10.1056/NEJM199908123410702) demonstrated that after a 3–4 year grass SCIT course, clinical remission persisted for at least 3 further years after stopping, with persistent immunologic changes. No pharmacotherapy produces post-treatment benefit.
Pro 3 — Pediatric asthma prevention. Jacobsen L et al. (Allergy 2007;62:943–948, DOI 10.1111/j.1398-9995.2007.01451.x) found an adjusted OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free at 10-year follow-up after 3 years of pediatric grass/birch SCIT.
Pro 4 — Venom protection. For Hymenoptera-allergic patients, Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of VIT-treated patients versus 39.8% of untreated controls (RR 0.10). Golden DBK et al. (JACI 2005;115:439–447) states VIT prevents systemic reactions in >95% of treated patients.
Con 1 — Time commitment. The standard course is 3–5 years per AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L et al., JACI 2011;127[1 Suppl]:S1–S55, DOI 10.1016/j.jaci.2010.09.034). Courses shorter than approximately 2 years are associated with weaker durability and higher relapse (Durham 1999).
Con 2 — Visit burden and observation requirement. Year 1 requires approximately 39 clinic visits (~26–28 weekly build-up injections plus early maintenance visits); Years 2–5 require approximately 14 visits per year. Every visit includes a mandatory 30-minute observation period, because most severe systemic reactions begin within 30 minutes (Cox 2011). That is roughly 39–40 hours of clinic time in Year 1 alone, before travel time.
Con 3 — Systemic-reaction risk. AAAAI/ACAAI surveillance (Epstein TG et al., JACIP 2014;2:161–167, DOI 10.1016/j.jaip.2014.01.004) found systemic reactions at a stable rate of 0.1% of injection visits across 23.3 million injection visits. Most are mild: 74% grade 1 (urticaria, flushing, rhinitis flare), 23% grade 2, 3% grade 3 anaphylactic. Historical fatality rate is approximately 1 per 2.5 million injections (Bernstein DI et al., JACI 2004;113:1129–1136); 1 confirmed fatality across 23.3 million injection visits in 2008–2012.
Con 4 — Real-world dropout. Only 43.9% of US AIT starters reach maintenance, and 23.9% never returned after their first injection per Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, DOI 10.1080/03007995.2021.1903848, MarketScan n=103,207). This means the evidence-grade pros are only realized by less than half of patients who begin treatment. Local reactions — occurring in approximately 16.3% of injections and 78.3% of patients (Calabria CW et al., LOCAL study, JACI 2009;124:739–744) — also contribute to patient burden.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The cons of SCIT (visit burden, time commitment) are largely tied to the traditional in-clinic model. The at-home allergy shot removes the weekly-clinic burden while keeping the shot itself: Curex delivers SCIT as one weekly self-administered shot at home, with Zoom-supervised first and changed doses and a prescribed epinephrine auto-injector on hand. SLIT — delivering the same disease-modification via the oral mucosa without injections — is a parallel needle-free route. For patients where the pros outweigh the cons, the at-home SCIT shot is the most direct choice; either at-home route is more honest than starting traditional clinic SCIT and joining the 23.9% dropout.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) | |||||
Antihistamines + intranasal corticosteroids |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients where the cons of the traditional model (3-5 years, ~39 Year-1 visits, in-clinic observation) outweigh the pros, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed by a board-certified allergist and self-administered as one weekly shot at home for $129/month. Your first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand — eliminating the visit-burden cons without sacrificing the disease-modification framework.
See if at-home shots are right for youFrequently asked questions
What are the biggest pros of allergy shots?
The four evidence-grade pros are: (1) symptom reduction — Cochrane SMD −0.73 across 51 RCTs and 2,871 patients (Calderón 2007); (2) durable post-treatment remission — ≥3 years of symptom control after stopping a 3–4 year course (Durham 1999); (3) pediatric asthma prevention — OR 4.6 for remaining asthma-free at 10-year follow-up (Jacobsen 2007, PAT study); and (4) venom protection — >95% protection against systemic sting reactions (Golden 2005), and 2.7% vs 39.8% in Cochrane 2012 (Boyle). These are not anecdote — they are derived from Cochrane meta-analyses, landmark RCTs, and prospective pediatric follow-up studies. For venom allergy especially, the pros are overwhelming.
What are the biggest cons of allergy shots?
The four major cons are: (1) time commitment — 3–5 year standard course per Cox 2011 PP3; (2) visit burden — approximately 39 Year-1 clinic visits with a mandatory 30-minute post-injection observation period after every injection; (3) systemic-reaction risk — 0.1% per injection visit (Epstein 2014 AAAAI/ACAAI surveillance, 23.3 million injection visits), with a historical fatality rate of approximately 1 per 2.5 million injections (Bernstein 2004); and (4) adherence failure — only 43.9% of US AIT starters reach maintenance and 23.9% never return after their first injection (Tkacz 2021, MarketScan n=103,207). The cons are largely logistical rather than biological — the therapy works, but many patients cannot sustain the schedule required to access the benefits.
Is the 30-minute wait after every shot a real requirement?
Yes — the 30-minute observation period after every injection is a standard-of-care requirement per the AAAAI/ACAAI/JCAAI Practice Parameter (Cox L et al., JACI 2011;127[1 Suppl]:S1–S55). The rationale is that the large majority of severe systemic reactions begin within 30 minutes of injection, allowing the clinic to identify and treat reactions before they progress to anaphylaxis. About 15% of systemic reactions have a delayed onset beyond 30 minutes (Epstein 2014), which is why some patients are given an epinephrine auto-injector for home use. The observation requirement adds approximately 30 minutes per visit — roughly 20 hours in Year 1 alone for the 39 required visits — and is a meaningful contributor to the dropout rate.
Do allergy shots cause any side effects?
Local injection-site reactions are the most common side effect: redness, swelling, and itching at the injection site occur in approximately 16.3% of injections and in about 78.3% of patients at some point during treatment (Calabria CW et al., LOCAL study, JACI 2009;124:739–744). Large local reactions (LLR, swelling >palm size) occur in about 0.4% of injections but do not reliably predict systemic reactions. Systemic reactions — involving areas beyond the injection site — occur in approximately 0.1% of injection visits per AAAAI/ACAAI surveillance (Epstein 2014). Most (74%) are mild (grade 1: urticaria, flushing, rhinitis flare), 23% are moderate (grade 2), and approximately 3% are grade 3 anaphylactic events. If you experience throat tightness, difficulty breathing, generalized hives, or lightheadedness after an injection, call 911 immediately and use an epinephrine auto-injector if available.
How does the dropout rate affect the pros and cons calculation?
The Tkacz 2021 dropout data fundamentally shapes the pros-and-cons calculation. Only 43.9% of US immunotherapy starters reach maintenance, and 23.9% never return after their first injection (Tkacz JP et al., Curr Med Res Opin 2021;37:957–965, MarketScan n=103,207). Because maximum benefit requires completing a 3–5 year course (Durham 1999 — durable remission requires a full course), the 56.1% who drop out experience the cons (time, money, local reactions) without accessing the full pros (durable remission, asthma prevention). This makes honest assessment of personal adherence capacity — before committing to SCIT — as important as evaluating the efficacy data. If sustained weekly clinic visits are not realistic, the pros-vs-cons balance tilts toward SLIT or pharmacotherapy.
Are allergy shots worth it for mild allergies?
For mild seasonal allergies well-controlled by an over-the-counter antihistamine and intranasal corticosteroid, the cons of SCIT likely outweigh the pros. SCIT is specifically indicated by Cox 2011 PP3 for persistent moderate-to-severe allergic rhinitis, conjunctivitis, or asthma that remains symptomatic despite optimized pharmacotherapy. For mild allergies, the time and cost investment of a 3–5 year in-clinic course — with its 0.1% systemic-reaction rate and 39 Year-1 visits — is disproportionate to the symptom burden. The calculus changes for Hymenoptera venom allergy (where the alternative is potentially fatal anaphylaxis), for children at risk of asthma (PAT OR 4.6), and for patients who prefer to eventually discontinue pharmacotherapy and achieve durable remission.
What are the pros and cons of allergy shots for kids?
Pros for children specifically include the pediatric asthma-prevention benefit documented in the PAT study (Jacobsen 2007, OR 4.6 for remaining asthma-free at 10-year follow-up) — a benefit not available to adults who have already developed asthma. Children with rhinitis who receive SCIT are also less likely to develop new sensitizations to additional allergens. Safety is generally good for pediatric patients; Cox 2011 PP3 recommends SCIT for children aged 5 years and older. Cons are similar to adults: weekly clinic visits, observation, and the procedure itself may be difficult for young children. An honest discussion with a pediatric allergist about the child's specific allergen profile, symptom burden, and asthma risk is the appropriate first step.
Related Articles
Purpose of Allergy Shots: Mechanism & Clinical Intent
Allergy shots induce immune tolerance — IgE to IgG4. Three intents: symptom relief (Cochrane SMD −0.73), less medication, and durable disease modification.
Read moreAllergy Shots for Pollen: Who Qualifies | Curex Guide
Yes, allergy shots target pollen via SCIT. Cox 2011 candidacy threshold, FDA SLIT tablets, per-allergen efficacy, and Curex at-home shots — all covered.
Read moreIs There an Allergy Shot? Overview Guide | Curex
Yes — allergy shots (SCIT) have been in US use since 1911. Cochrane SMD −0.73 (51 RCTs). Works for environmental allergens and venom. NOT for food allergy. 3–5 yr course.
Read moreAllergy Shot Schedule: Full Timeline Guide | Curex
Allergy shot schedule: weekly build-up 24–28 wks, maintenance every 2–4 wks × 3–5 yrs (Cox 2011). Cluster, rush variants and at-home option explained.
Read moreAllergy Shots Benefits – QoL & Outcomes | Curex Guide
Allergy shots benefits: QoL RQLQ 0.8 (Walker 2001), symptom SMD -0.73, medication SMD -0.57, asthma prevention OR 4.6, >=3-yr post-treatment remission.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.